Adverse effects of androgen-deprivation therapy in prostate cancer and their management-Reference-Cited by-同舟云学术

Adverse effects of androgen-deprivation therapy in prostate cancer and their management

Published:2015-04 Issue: Volume:115 Page:3-13
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Rhee Handoo¹²,Gunter Jennifer H.²,Heathcote Peter¹²,Ho Ken³,Stricker Phillip⁴,Corcoran Niall M.⁵,Nelson Colleen C.²

Affiliation:

1. Department of Urology; Princess Alexandra Hospital; QLD Australia

2. Australian Prostate Cancer Research Centre; Institute of Health and Biomedical Innovation; Queensland University of Technology; Princess Alexandra Hospital; Translational Research Institute; QLD Australia

3. Centre for Health Research; Princess Alexandra Hospital; QLD Australia

4. Garvan Institute of Medical Research and The Kinghorn Cancer Centre; Darlinghurst NSW Australia

5. Epworth Prostate Centre; Epworth Healthcare; Melbourne Australia

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12964/fullpdf

Reference64 articles.

1. Contemporary role of androgen deprivation therapy for prostate cancer;Pagliarulo;Eur Urol,2012

2. Mottet N Bastian PJ Bellmunt J Guidelines on prostate cancer 2014 http://www.uroweb.org/gls/pdf/09%20Prostate%20Cancer_LRLV2.pdf

3. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up;Studer;Eur Urol,2014

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer;Steroids;2024-10

2. Creatine supplementation does not add to resistance training effects in prostate cancer patients under androgen deprivation therapy: a double-blind randomized trial;Journal of Science and Medicine in Sport;2024-09

3. Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator–activated receptor promotes enzalutamide resistance in prostate cancer;Free Radical Biology and Medicine;2024-08

4. Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies;ESMO Open;2024-07

5. Effectiveness of educational and psychological survivorship interventions to improve health-related quality of life outcomes for men with prostate cancer on androgen deprivation therapy: a systematic review;BMJ Open;2024-05